{"denoms":[{"counts":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"58"}],"units":"Participants"}],"groups":[{"description":"Alisertib 25 or 35 mg, Powder-in-Capsule (PIC) formulation, orally, once daily (QD) for 21 days followed by a 7-day recovery period in 28-day cycles or alisertib 35, 45, 65 or 90 mg PIC, orally, QD for 14 days followed by a 14-day recovery period in 28-day cycles, until disease progression or unacceptable alisertib-related toxicity (up to 14 cycles). All participants received an initial starting dosage of alisertib PIC 25 mg, orally, twice daily (BID) on Day 1 (loading dose), followed by their respective dosage assignment.","id":"BG000","title":"Part 1: PIC Dose Escalation"},{"description":"Alisertib 40 mg, Enteric-coated Tablet (ECT) formulation, orally, QD for 14 days followed by a 14-day recovery period in 28-day cycles, or alisertib 30, 40 or 50 mg ECT, orally BID for 7 days followed by a 14-day recovery period in 21-day cycles, until disease progression or unacceptable alisertib-related toxicity (up to 15 cycles).","id":"BG001","title":"Part 1: ECT Dose Escalation"},{"description":"Participants with peripheral T-cell lymphoma (PTCL) received alisertib 50 mg ECT, orally, BID for 7 days followed by a 14-day recovery period in 21-day cycles, until disease progression or unacceptable alisertib-related toxicity (up to 2 cycles).","id":"BG002","title":"Part 2: PTCL"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"8.91","value":"61.4"},{"groupId":"BG001","spread":"14.22","value":"59.5"},{"groupId":"BG002","spread":"24.04","value":"63.0"},{"groupId":"BG003","spread":"12.03","value":"60.5"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"58"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"31"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"27"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"58"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"16"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"41"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}],"title":"Unknown or Not Reported"}],"denoms":[{"counts":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"58"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"52"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"58"}],"units":"Participants"}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"4"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"58"}],"units":"Participants"}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"58"}],"units":"Participants"}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"58"}],"units":"Participants"}],"title":"Not Reported"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"58"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"58"}],"units":"Participants"}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.25","value":"165.9"},{"groupId":"BG001","spread":"10.95","value":"164.6"},{"groupId":"BG002","spread":"6.43","value":"160.6"},{"groupId":"BG003","spread":"10.89","value":"165.1"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"56"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","populationDescription":"Here number analyzed is the number of participants who were evaluated for height at baseline.","title":"Height","unitOfMeasure":"cm"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"20.031","value":"81.40"},{"groupId":"BG001","spread":"19.747","value":"77.62"},{"groupId":"BG002","spread":"43.911","value":"97.65"},{"groupId":"BG003","spread":"20.573","value":"80.13"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"58"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Weight","unitOfMeasure":"kg"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"0.282","value":"1.93"},{"groupId":"BG001","spread":"0.289","value":"1.88"},{"groupId":"BG002","spread":"0.434","value":"2.05"},{"groupId":"BG003","spread":"0.286","value":"1.91"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"56"}],"units":"Participants"}]}],"description":"Body Surface Area =square root \\[height (cm) \\* weight (kg) / 3600\\].","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","populationDescription":"Here number analyzed is the number of participants who were evaluated for body surface area at baseline.","title":"Body Surface Area","unitOfMeasure":"m^2"}],"populationDescription":"Safety population is defined as all participants who received any amount of alisertib."}